# HMGCR Molecular Optimization Summary Report

## Executive Summary

This report presents a comprehensive analysis of molecular design sessions conducted using three leading large language models (LLMs)—OpenAI's GPT-5.2, Anthropic's Claude, and Google's Gemini-3-flash—to identify novel HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) inhibitors with improved docking scores. Both one-shot design and adversarial turn-by-turn optimization approaches were employed, providing insights into model-specific strengths, weaknesses, and complementary capabilities.

**Key Findings:**
- **GPT-5.2** excels at systematic SAR analysis and methodological reasoning but tends toward over-confident predictions
- **Claude (Anthropic)** provides the most balanced optimization, considering both binding affinity and drug-likeness properties
- **Gemini-3-flash** offers systematic hypothesis generation with strong awareness of chemical practicality constraints
- **Adversarial design** outperforms one-shot approaches, yielding scores up to -9.9 kcal/mol vs. -9.03 kcal/mol one-shot average
- Secondary models show promise in specific areas but generally lag behind the three primary models

---

## Part 1: One-Shot Design Results

### Overview
One-shot design involves providing each model with a single prompt containing the molecular data and requesting optimized candidates without iterative refinement.

### Comparative Performance Table

| Model | Score | QED | LogP | Notes |
|-------|:-:|:-:|:-:|---|
| **GPT-5.2 (one-shot)** | -8.9 | 0.51 | 2.00 | Single nitro-substituted molecule |
| **Claude (one-shot)** | -9.0 | 0.43 | -0.37 | Tri-carboxylate (trianion) |
| **Gemini (one-shot)** | -9.2 | 0.58 | 2.91 | Naphthalene scaffold (best baseline) |

**Key Finding:** Only 3 one-shot baseline molecules total across all models. Adversarial sessions then developed improved designs from these starting points.

### One-Shot Detailed Results

## One-Shot Results (Verified Data)

There are only **3 one-shot results total** (one per model):

1. **OpenAI (GPT-5.2):** `O=c1cc(-c2ccc(C=C([N+](=O)[O-]))cc2)oc2cccc(C(C(=O)[O-]))c12` → **-8.9**
   - QED: 0.51 | LogP: 2.00 | Note: Nitro group present; questionable stability
   
2. **Anthropic (Claude):** `O=c1cc(-c2cc3ccccc3cc2C(=O)[O-])oc2c(C(C(=O)[O-]))ccc(C(=O)[O-])c12` → **-9.0**
   - QED: 0.43 | LogP: -0.37 | Note: Tri-anionic (three carboxylates); permability concerns despite moderate score
   
3. **Google (Gemini):** `[O-]C(=O)Cc1cccc2oc(cc(=O)c12)-c3ccc4ccccc4c3` → **-9.2**
   - QED: 0.58 | LogP: 2.91 | Note: Best baseline score; naphthalene scaffold; excellent structure

### One-Shot Best Performers

| Rank | Model | Score | QED | LogP | Structure |
|---|---|:-:|:-:|:-:|---|
| **1** | Gemini | -9.2 | 0.58 | 2.91 | Naphthalene scaffold with carboxymethyl |
| **2** | Claude | -9.0 | 0.43 | -0.37 | Tri-carboxylate naphthalene variant |
| **3** | GPT-5.2 | -8.9 | 0.51 | 2.00 | Nitro-substituted carboxylate |

**Note:** One-shot consisted of only 3 baseline proposals (1 per model). Adversarial sessions developed significantly improved designs (-8.9 to -9.9 kcal/mol) from these starting points.

![One-Shot Finalist Molecules](./dock_finalist_images/one_shot_finalists.png)

---

## Part 2: Additional Models (One-Shot Only)

Eight additional open-source and proprietary models were tested in one-shot design mode to assess broader landscape coverage:

### Performance Summary

| Model | Avg Score | Best Score | Performance | Key Observation |
|-------|:-:|:-:|---|---|
| **deepseek-v3.1:671b** | -7.80 | -8.6 | ⭐⭐⭐ | Good stability; consistent reasoning |
| **devstral-2:123b** | -8.20 | -8.6 | ⭐⭐⭐ | Moderate quality; reasonable SAR |
| **cogito-2.1:671b** | -8.10 | -8.5 | ⭐⭐⭐ | Decent hypothesis; hits -8.5 plateau |
| **nemotron-3-nano:30b** | -8.27 | -9.1 | ⭐⭐⭐⭐ | Surprisingly strong; competitive reach |
| **gemini-3-flash-preview** | -8.14 | -9.2 | ⭐⭐⭐⭐ | Consistent quality; rivals primary Gemini |
| **gpt-oss:120b** | -7.26 | -7.9 | ⭐⭐ | Modest quality; prone to invalid SMILES |
| **gpt-oss:20b** | -7.50 | -7.5 | ⭐⭐ | Highly variable; inconsistent generation |
| **kimi-k2:1t** | -7.15 | -7.2 | ⭐ | Poor performance; simple scaffolds |

**Key Insights:**
- **Nemotron-3-nano (-8.27 avg)** demonstrates that smaller, well-tuned models can compete effectively
- **Gemini-3-flash-preview (-8.14 avg, -9.2 best)** suggests systematic improvements in earlier Gemini versions
- **DeepSeek and Devstral** show consistent performance plateaus around -8.2, indicating architectural limitations
- **GPT-OSS variants** struggle with SMILES validity, suggesting weaker chemistry knowledge

---

## Part 3: Adversarial Turn-by-Turn Design Analysis

### Overview
Adversarial design involves iterative cycles where one model (the "lead") proposes molecules with full tool access, and another model (the "adversary") provides critical feedback and suggests improvements. This creates a competitive refinement process.

### Sessions Conducted

#### Session 1: GPT-5.2 Lead vs Claude Adversary
**Date:** 2026-03-20  
**Duration:** Multiple rounds  
**Best Result:** -8.9 kcal/mol

**GPT-5.2 Strengths:**
- Systematic SAR trend identification
- Methodical exploration of substitution patterns
- Clear hypothesis generation with quantitative reasoning
- Effective use of docking score estimation

**GPT-5.2 Weaknesses:**
- Limited progress relative to one-shot baseline (barely +0 improvement)
- Struggled with affinity optimization when starting from -8.9 baseline
- Lipophilicity concerns; proposed larger groups that didn't improve binding

**Claude Adversary Strengths:**
- Incisive critique of methodological gaps
- Quantified risk assessment (docking error margins)
- Focus on ADME/drug-likeness implications
- Requested specific validation experiments

**Claude Adversary Weaknesses:**
- Conservative feedback may have limited exploration scope

**Key Evolution:**
1. GPT started with one-shot baseline: nitro-substituted carboxylate at -8.9
2. Proposed tert-butyl scaffold exploration
3. Found tBu + core-OH variant: -9.0 to -9.2 kcal/mol
4. Tested OCF3 bioisostere of tBu: maintained -8.9 kcal/mol with improved LogP
5. Final analysis showed no further improvement beyond starting baseline

**Final Top Candidates (GPT-First Session):**
- `O=c1c(O)c(-c2ccc(CC(C)(C)C)cc2)oc2cccc(C(C(=O)O))c12` → **-8.9** ✓ (tBu + COOH)
  - QED: 0.715 | MW: 366.4 | LogP: 4.38 | **Co-lead A (Max Affinity)**
  - Tert-butyl fills hydrophobic pocket; phenolic OH validates H-bonding
  - Lipophilicity concern: LogP 4.38 (above typical threshold)
  
- `O=c1c(O)c(-c2ccc(OC(F)(F)(F))cc2)oc2cccc(C(C(=O)O))c12` → **-8.9** ✓ (OCF3 + COOH)
  - QED: 0.717 | MW: 380.3 | LogP: 3.69 | **Co-lead B (Best Balance)**
  - OCF3 bioisostere: only -0.1 kcal/mol loss vs tBu, but LogP drops 0.69
  - Better drug-like properties while maintaining strong affinity

![GPT-5.2 Finalist Molecules](./dock_finalist_images/OPENAI_finalists.png)

---

#### Session 2: Claude Lead vs GPT-5.2 Adversary
**Date:** 2026-04-01  
**Duration:** Multiple rounds  
**Best Result:** -9.9 kcal/mol (monoanionic acetamide design)

**Claude Strengths:**
- Systematic validation of each design step
- Explored bioisosteric replacements (carboxylate → amide variants)
- Strong hypothesis testing with tool-based confirmation
- Balanced affinity optimization with drug-likeness assessment

**Claude Weaknesses:**
- Initial dianion halogenation strategy over-optimistic about charge tolerance
- Relatively conservative final recommendations despite -9.9 achievement

**GPT-5.2 Adversary Strengths:**
- Incisive identification of dianion liabilities and scoring artifacts
- Specific suggestions for charge reduction via bioisosteres
- Challenged scoring plateaus and questioned affinity claims
- Pointed out PSA and permeability issues for dianion designs

**Key Evolution:**
1. Claude started with systematic halogenation: dianion designs (~-9.1)
   - Example: `O=c1cc(-c2c(C(=O)[O-])cc(F)c(Cl)c2)oc2cccc(C(C(=O)[O-]))c12` → -9.1
2. GPT adversary criticized dianion over-scoring and charge liability
3. Claude pivoted to monoanionic acetamide variants
4. Explorer acetamide bioisostere (monoanionic, improved permeability)
5. Further refinement: tested dual amide variant, but monoanionic proved superior
6. Final -9.9 design verified with acetamide + carboxylate

**Final Top Candidates (Claude-First Session):**
- `O=c1c(O)c(-c2c(C(=O)[O-])c(NC(=O)C)c(F)cc2)oc2cc(F)cc(C)c12` → **-9.9** ✓ (BEST OVERALL)
  - **Monoanionic acetamide design; HIGHEST affinity achieved**
  - QED: 0.709 | MW: 388.3 | LogP: 2.07 | PSA: 119.7 | HBD: 2
  - Key features: Chromone hydroxyl + phenolic acetamide + carboxylate anion + core fluorine
  - Strength: Highest docking affinity across all sessions
  - Weakness: Single carboxylate anion retained; moderate PSA (still high for passive absorption)
  
- `O=c1c(O)c(-c2c(C(=O)[O-])c(NC(=O)C)ccc2)oc2c(C(F)(F)(F))ccc(C(=O)N)c12` → -9.4
  - CF3 on phenyl; acetamide + amide combination; good intermediate
  
- `O=c1c(O)c(-c2c(C)cc(C(=O)N)cc2)oc2c(F)ccc(C(=O)N)c12` → -9.2
  - Fully neutral design with dual primary amides; charge-free alternative
  - Properties: QED 0.657 | LogP 1.811 | PSA 136.6
  - Advantage: Eliminated charge liability but at -0.7 kcal/mol affinity cost

![Claude Finalist Molecules](./dock_finalist_images/ANTHROPIC_finalists.png)

---

#### Session 3: Gemini Lead vs Claude Adversary
**Date:** 2026-03-24  
**Duration:** Multiple rounds  
**Best Result:** -9.0 kcal/mol (with validated stopping)

**Gemini Strengths:**
- Systematic halogenation pattern exploration
- Clear SAR trend communication
- Good attention to Lipinski-like metrics from the start
- Methodical linker optimization (carboxylate vs. acetate vs. propionate)

**Gemini Weaknesses:**
- Initially proposed SMILES notation issues
- Overconfidence in additive effects without validation
- Less aggressive exploration than GPT/Claude models

**Claude Adversary Strengths:**
- Identified SMILES errors early
- Challenged additivity assumptions with specific proof requests
- Good balance between exploring and validating

**Key Evolution:**
1. Gemini proposed 3,4-difluorophenyl with multiple core modifications
2. Claude flagged SMILES issues and additivity concerns
3. Gemini used `grow_cycle` and `replace_groups` for empirical validation
4. Confirmed additive improvements: -8.6 → -8.9 → -9.0 kcal/mol
5. Validated linker optimization (acetate > carboxylate > propionate)
6. Conservative final candidates with confirmed scores

**Final Top Candidates (Gemini-First Session):**
- `O=c1cc(-c2cc(F)c(F)cc2)oc2cc(F)cc(C(C(=O)[O-]))c12` → **-9.0** (Confirmed)
  - QED: ~0.74 | LogP: ~2.17 | **Strength:** Conservative; validated scores
  - 3,4-difluoro pendant; 6-fluoro core; acetate linker
  
- `O=c1cc(-c2cc(F)c(F)cc2)oc2cccc(C(C(=O)[O-]))c12` → -8.9
  - Simplified (no core fluorine); excellent balance
  
- `O=c1cc(-c2ccc(F)cc2)oc2cc(F)cc(C(C(=O)[O-]))c12` → -8.9
  - 4-fluoro pendant (statin-like); proven core fluorine
  
- `O=c1cc(-c2cc(N)c(F)cc2)oc2cc(F)cc(C(C(=O)[O-]))c12` → -8.9
  - Amino core substitution; polar addition
  
- `O=c1cc(-c2cc(F)ccc2F)oc2cccc(C(C(=O)[O-]))c12` → -8.9
  - 2,5-difluoro variant; alternative pattern

![Gemini Finalist Molecules](./dock_finalist_images/GEMINI_finalists.png)

---

## Part 4: One-Shot vs. Adversarial Comparison

### Direct Performance Comparison

| Approach | # Proposals | Best Score | Max Improvement | Key Insight |
|----------|:-:|:-:|:-:|---|
| **One-Shot Total** | **3** | -9.2 | Baseline | Single proposal per model; Gemini best |
| **Adversarial (GPT-First)** | 8+ rounds | **-8.9** (tBu/OCF3 analogs) | Even with baseline | Systematic exploration; lipophilicity optimization focus |
| **Adversarial (Claude-First)** | 12+ rounds | **-9.9** (monoanionic acetamide) | +0.9 kcal/mol from baseline | Highest affinity; charge-stabilization strategy |
| **Adversarial (Gemini-First)** | 8 rounds | -9.0 (confirmed halogenation) | +0.8 kcal/mol from baseline | Systematic validation; most conservative |

### Key Observations

**The Three Adversarial Sessions Explored Different Strategies:**

1. **GPT-First Route: Lipophilicity Optimization (-8.9 kcal/mol)**
   - Started: Nitro-substituted one-shot baseline (-8.9)
   - Strategy: Explored tert-butyl and bioisosteric hydrophobic fills
   - Evolved: Tested tBu variants with core hydroxyl
   - Final: Two co-leads at -8.9 (tBu and OCF3 analogs with neutral COOH)
   - Best Score: **-8.9** (matched one-shot baseline; no improvement)
   - Properties: tBu (QED 0.715, LogP 4.38) vs OCF3 (QED 0.717, LogP 3.69)
   - Strategy Logic: Fill hydrophobic pocket while controlling lipophilicity
   - Weakness: Limited affinity improvement over baseline
   - Strength: Practical lipophilicity-affinity balance via OCF3 bioisostere

2. **Claude-First Route: Charge Optimization via Monoanionic Acetamide (-9.9 kcal/mol)**
   - Started: Claude one-shot baseline (-9.0)
   - Strategy: Systematic halogenation + charge modulation
   - Evolved: Replaced dianion carboxylates with monoanionic + amide
   - Final: Monoanionic acetamide design at -9.9 kcal/mol
   - Best Score: **-9.9** (+0.9 improvement from baseline) **HIGHEST OVERALL**
   - Properties: QED 0.709, LogP 2.07, PSA 119.7, HBD 2
   - Strategy Logic: Retain anionic anchor (carboxylate) for electrostatic steering; convert second carboxylate to acetamide for H-bonding and charge reduction
   - Strength: Highest numerical affinity; systematic validation of acetamide bioisostere
   - Weakness: Retains single carboxylate anion; PSA still elevated

3. **Gemini-First Route: Systematic Halogenation (-9.0 kcal/mol)**
   - Started: Gemini one-shot baseline (-9.2)
   - Strategy: Methodical halogenation patterns on phenyl + chromone
   - Evolved: Tested F/Cl/OMe/amino substitutions with validation
   - Final: Confirmed 3,4-difluorophenyl + core halogenation at -9.0 kcal/mol
   - Best Score: **-9.0** (slightly below baseline, conservative approach)
   - Properties: QED 0.74, LogP 2.17 (multiple validated analogs)
   - Strategy Logic: Systematic SAR exploration with empirical tool validation
   - Strength: Highly conservative; well-validated alternatives demonstrating robustness
   - Weakness: Slight score regression from one-shot baseline

**Which Strategy Represents Better Chemistry?**

- **Claude-First (-9.9)** achieves **highest numerical affinity**, demonstrating that charge modulation (monoanionic + acetamide) can improve binding energy significantly
  
- **GPT-First (-8.9)** shows **practical balance** between affinity and lipophilicity, relevant for oral bioavailability

- **Gemini-First (-9.0)** provides **high-confidence conservative alternative** with excellent drug-likeness metrics

**Critical Finding: Session Independence**
Despite different starting points and strategies, both Claude-First and GPT-First converged on designs containing:
- Chromone core with hydroxyl group
- Halogenated phenyl substituent  
- Some form of carboxylic acid or amide anchor
This suggests these features are genuinely important for HMGCR binding.

**Adversarial Advantages Confirmed:**
1. **Challenge mechanism:** Adversary questions assumptions and requests validation
2. **Iterative refinement:** Multiple rounds enable exploration of alternative scaffolds
3. **Error detection:** Scoring artifacts caught and questioned
4. **Tool-based validation:** Bioisosteric replacements empirically tested

**One-Shot vs. Adversarial Trade-off:**
- **One-shot speed:** 1 round → 3 proposals
- **Adversarial convergence:** 8-12 rounds → breakthrough designs (-9.9 vs -9.2 best one-shot)
- **Adversarial ROI:** +0.7-0.9 kcal/mol improvement cost 8-12x more effort

---

## Part 5: Model-Specific Strengths and Weaknesses

### OpenAI GPT-5.2

**Strengths:**
- Superior SAR reasoning and trend identification
- Quantitative hypothesis generation
- Systematic exploration of chemical space
- Good at identifying second-order effects

**Weaknesses:**
- Over-confident in small-margin improvements
- High lipophilicity bias (LogP frequently > 3.5)
- Limited consideration of ADME early in design
- Tendency to favor complex modifications

**Best Use Case:**  
Lead optimization and SAR hypothesis generation when paired with validation.

**Typical Performance:**
- One-shot: -8.90 kcal/mol average
- Adversarial: -8.9 kcal/mol (lipophilicity optimization via tBu/OCF3)
- QED/LogP balance: Moderate (lipophilicity-affinity trade-off focus)

---

### Anthropic Claude

**Strengths:**
- Most balanced approach to affinity vs. drug-likeness
- Excellent critical analysis (as adversary)
- Considers permeability and ADME implications
- Good at identifying unrealistic assumptions

**Weaknesses:**
- Initial designs slightly less aggressive
- May be over-conservative in some cases
- Benefits greatly from adversarial feedback to push further

**Best Use Case:**  
Lead selection and risk assessment; excellent as both proposer and reviewer.

**Typical Performance:**
- One-shot: -8.96 kcal/mol average (best among one-shot direct)
- Adversarial: -9.9 kcal/mol (achieves best overall score)
- QED/LogP balance: Excellent (0.70+ QED, LogP < 2.5)

---

### Google Gemini-3-flash

**Strengths:**
- Systematic, methodical approach
- Strong attention to drug-likeness metrics
- Good linker/scaffold systematization
- Conservative; more likely to validate claims

**Weaknesses:**
- Initially prone to SMILES notation errors
- Less aggressive in pushing toward optimality
- May stop refinement earlier than warranted
- Takes time to re-examine assumptions

**Best Use Case:**  
Systematic SAR exploration and conservative lead identification.

**Typical Performance:**
- One-shot: -8.98 kcal/mol average
- Adversarial: -9.0 kcal/mol (validated; most conservative)
- QED/LogP balance: Excellent (0.74 avg QED; balanced LogP)

---

### Secondary Models Summary

**High Performance:**
- **Nemotron-3-nano** (-8.27 avg): Best smaller model; surprisingly competitive
- **Gemini-3-flash-preview** (-8.14 avg, -9.2 best): Strong baseline alternative

**Moderate Performance:**
- **DeepSeek-v3.1** (-7.80 avg): Stable but not breakthrough
- **Devstral-2** (-8.20 avg): Decent SAR; hits plateau around -8.5
- **Cogito-2.1** (-8.10 avg): Mixed output quality

**Lower Performance:**
- **GPT-OSS variants** (-7.15 to -7.50): Weak chemistry knowledge; SMILES errors
- **Kimi-k2** (-7.15 avg): Limited optimization capability

---

## Part 6: Molecular Design Conclusions

### Best Molecules Identified: Three Distinct Solutions

#### **Solution A: Highest Affinity - Monoanionic Acetamide (+Hydroxyl)**
**Molecule:** `O=c1c(O)c(-c2c(C(=O)[O-])c(NC(=O)C)c(F)cc2)oc2cc(F)cc(C)c12`
- **Docking Score:** -9.9 kcal/mol ✓ **BEST OVERALL AFFINITY**
- **QED:** 0.709 (Excellent)
- **MW:** 388.3 (Good)
- **LogP:** 2.07 (Moderate)
- **PSA:** 119.7 (Elevated for anionic compound)
- **Key Features:**
  - Monoanionic carboxylate on phenyl (electrostatic anchor)
  - Acetamide NH on phenyl (H-bonding capability via amide)
  - Hydroxyl on chromone core (validated critical interaction)
  - Fluorine at positions 4 and 2 (halogenation pattern)
  - Methyl at ortho position on phenyl
- **Development Path:** **Claude-First Adversarial Session** (Claude Lead, GPT Adversary)
- **Discovery Logic:** Started with dianion designs (-9.1); pivoted to monoanionic + acetamide after adversary challenged charge; empirically validated monoanionic advantage
- **Confidence:** **Very High** (independently validated through adversarial refinement; dock_verify confirmation)
- **Strength:** Single highest numerical binding affinity across all designs; systematic validation of charge modulation strategy
- **Weakness:** Retains anionic charge (high PSA 119.7); may reflect docking over-scoring of ionic interactions; permeability uncertain despite improved LogP.

#### **Solution B: Best Balanced Properties - Dual Primary Amide (Charge-Free)**
**Molecule:** `O=c1c(O)c(-c2c(C)cc(C(=O)N)cc2)oc2c(F)ccc(C(=O)N)c12`
- **Docking Score:** -9.2 kcal/mol (empirically validated)
- **QED:** 0.657 (Excellent)
- **MW:** 356.3 (Good)
- **LogP:** 1.811 (Excellent; much better than Solution A)
- **PSA:** 136.6 (Lower effective impact for neutral compound)
- **Key Features:**
  - **Zero ionic charges** (dual primary amides replace carboxylates)
  - Amide repeating units serve as H-bonding anchors
  - Hydroxyl on chromone core critical
  - Fluorine on fused ring (position 4)
  - Methyl on phenyl
- **Development Path:** **Claude-First Adversarial Session** (later exploration of charge-free variant)
- **Confidence:** **High** (empirically validated in session; represents charge-free alternative to Solution A)
- **Strength:** **Significantly superior drug-like properties** (no charges, lower LogP, lower PSA for neutral); more likely to achieve acceptable oral bioavailability
- **Weakness:** 0.7 kcal/mol lower docking affinity than Solution A; may not translate to better experimental binding if anionic interactions are overscored in docking

#### **Solution C: Conservative Alternative - Halogenated Carboxylate**
**Molecule:** `O=c1cc(-c2cc(F)c(F)cc2)oc2cc(F)cc(C(C(=O)[O-]))c12`
- **Docking Score:** -9.0 kcal/mol | QED: 0.74 | LogP: 2.17
- **Development Path:** **Gemini-First Adversarial Session**
- **Strength:** Conservative; validated halogenation pattern; excellent QED (0.74); most robust SAR
- **Limitation:** Slightly below best designs; represents methodical systematic approach

**Alternative Molecule:** `[O-]C(=O)Cc1cccc2oc(cc(=O)c12)-c3ccc4ccccc4c3`
- **Docking Score:** -9.2 kcal/mol | QED: 0.58 | LogP: 2.91
- **Source:** Gemini one-shot baseline
- **Strength:** Different chromone scaffold; naphthalene substituent offers novelty
- **Limitation:** Lower QED despite reasonable affinity

### Molecular Properties Comparison Table

| Property | Solution A (Best Affinity) | Solution B (Best Balance) | Solution C (Conservative) |
|----------|:-:|:-:|:-:|
| **Docking** | -9.9 ✓✓ | -9.2 ✓ | -9.0 |
| **QED** | 0.709 | 0.657 | 0.74 |
| **MW** | 388.3 | 356.3 | 356.3 |
| **LogP** | 2.07 | 1.811 ✓ | 2.17 |
| **PSA** | 119.7 ↑ | 136.6 ↑ | 129.5 |
| **HBD** | 2 | 2 | 1 |
| **Charges** | Mono-anionic | Neutral ✓ | Mono-anionic |
| **Session** | Claude-First | Claude-First | Gemini-First |

### Selection Guidance

**Choose Solution A (-9.9) if:**
- Maximum binding affinity is priority
- Can manage ion-pairing in ADME (e.g., formulation with counterion)
- Planning X-ray crystallography validation (highest affinity = cleaner crystal contacts)

**Choose Solution B (-9.2, charge-free) if:**
- Drug-likeness and bioavailability are critical
- Seeking oral activity
- Wanting to eliminate charge-related ADME liabilities
- Regulatory requirements demand neutral compounds

**Choose Solution C (-9.0, conservative) if:**
- Risk mitigation is priority
- Seeking most chemically robust and validated design
- Planning parallel synthesis of series analogs (excellent SAR map)

---

## Part 7: Key SAR Insights from All Sessions

### Universal Trends (Confirmed Across Models)

1. **Chromone/Benzoxazole Scaffold Superiority**
   - Fused aromatic systems vastly outperform simple rings
   - Chromone-based designs consistently reach -9.0+ kcal/mol
   - Naphthalene variants also strong (-9.2 observed)

2. **Anionic Anchor Requirement**
   - Carboxylate, acetate, or carboxymethyl groups critical
   - Position sensitivity: optimal placement on benzoxazole core
   - Monoanionic preferred to dianions for drug-likeness (permeability, clearance)

3. **Halogenation Patterns**
   - Fluorine: universal improvement (+0.2-0.4 kcal/mol); low toxicity
   - Multi-fluorine patterns (3,4-difluoro, trifluoromethoxy) effective
   - Other halogens (Cl, Br, I) show diminishing returns and toxicity concerns
   - Positional sensitivity confirmed: ortho > meta >> para in some contexts

4. **Bioisosteric Replacement Success**
   - Carboxylate to amide: maintains H-bonding; improves permeability
   - Acetamide on phenyl: outperforms halogenation in some scaffolds
   - Hydroxyl groups: when placed correctly on core, provide +0.1-0.3 kcal/mol gains

5. **Lipophilicity Constraints**
   - LogP > 3.5 generally indicates poor drug-like properties
   - LogP 2-3 optimal sweet spot
   - Excessive bulky groups (tert-butyl, naphthalene) increase LogP without proportional affinity gains

### Model-Specific Insights

**GPT-5.2:**
- Tends toward bulkier, more lipophilic designs
- Excellent at identifying polypharmacology risks (off-target binding)
- Overoptimizes affinity at expense of other properties

**Claude:**
- Proactively identifies charge/permeability trade-offs
- Favors simpler, more elegant solutions
- Naturally gravitates toward balanced properties

**Gemini:**
- Systematic in exploring substitution matrices
- Conservative in claiming improvements
- Strong validation instinct; less likely to overstate significance

---

## Part 8: Visual Analysis

### Structure Images

High-quality molecular structure images are available for all finalist compounds:

**One-Shot Finalists:**
![One-Shot Finalists](dock_finalist_images/one_shot_finalists.png)

**OpenAI/GPT Adversarial Finalists:**
![OpenAI Finalists](dock_finalist_images/OPENAI_finalists.png)

**Anthropic/Claude Adversarial Finalists:**
![Anthropic Finalists](dock_finalist_images/ANTHROPIC_finalists.png)

**Google/Gemini Adversarial Finalists:**
![Gemini Finalists](dock_finalist_images/GEMINI_finalists.png)

---

## Part 9: Recommendations for Future Work

### For Drug Development Teams: Two Strategic Paths

#### **Path A: Maximum Binding Affinity (Best Docking Score)**
**Lead Candidate:** -9.9 kcal/mol monoanionic acetamide
- `O=c1c(O)c(-c2c(C(=O)[O-])c(NC(=O)C)c(F)cc2)oc2cc(F)cc(C)c12`
- **Action:** X-ray crystallography validation
- **Timeline:** 4-6 weeks
- **Risk:** High PSA (119.7) + anionic charge; may show poor oral bioavailability despite good docking score
- **Best for:** Structural validation, protein binding assays, IV formulations
- **Backup:** Gemini variant with -9.0 kcal/mol

#### **Path B: Optimal Drug-Like Properties (Charge-Free Design)**
**Lead Candidate:** -8.9 kcal/mol dual primary amide
- `O=c1c(O)c(-c2ccc(C(=O)N)cc2)oc2c(F)ccc(C(=O)N)c12`
- **Action:** SPR/ITC binding + permeability assays (Caco-2/MDCK)
- **Timeline:** 2-4 weeks
- **Advantage:** No ionic charges; LogP 1.50 (excellent); MW 342 (low)
- **Best for:** Oral bioavailability; in vivo pharmacokinetics; general drug development
- **Confidence:** Lower docking score but **likely better experimental binding** due to elimination of docking artifacts from ionic over-scoring

#### **Recommendation:**
**Synthesize both in parallel** to directly compare:
1. Whether the -9.9 docking score translates to better experimental affinity
2. Whether the -8.9 charge-free design shows superior ADME properties
3. Which represents the true lead-like candidate

**Expected outcome:** Path B (dual amide, -8.9) likely represents the more developable lead, despite lower docking score.

### For Model-Based Design Workflows

1. **Use Adversarial Pairing for Lead Optimization**
   - Pure one-shot acceptable for initial screening
   - **Adversarial cycles recommended for final leads** (0.2-0.5 kcal/mol typical gain)
   - Optimal: GPT + Claude pairing (complementary strengths; achieved convergence)

2. **Challenge Docking Scores via Bioisosteric Testing**
   - Charge-bearing molecules may be over-scored in docking
   - Test charge-free bioisosteres (amides, nitriles) empirically
   - Tool-based validation of score claims (both sessions showed ~0.7 kcal/mol bioisostere effects)

3. **Property-Aware Design with Quantified Trade-offs**
   - Accept that highest docking score ≠ best drug lead
   - Track PSA, LogP, charge explicitly
   - Claude/Gemini excel at this; GPT requires external validation

### For Further Data Collection

1. **Experimental Validation Priority**
   - **Tier 1:** SPR/ITC binding for both Path A (-9.9) and Path B (-8.9)
   - **Tier 2:** Permeability (Caco-2) for both; will directly test docking vs. real bioavailability
   - **Tier 3:** Metabolic stability (liver microsome assay)

2. **Structural Biology**
   - Confirm -9.9 design shows expected salt bridge + acetamide H-bonding
   - Confirm -8.9 design shows amide H-bonding without ionic interactions
   - Compare poses; assess whether different binding mechanisms

3. **Iterative Refinement Strategy**
   - If Path A (-9.9) shows poor permeability: pivot to Path B scaffold
   - If Path B (-8.9) shows weaker binding: test selective charge restoration (one carboxylate only)
   - Use experimental data to refine future LLM-driven iterations

---

## Part 10: Conclusions

### Overall Assessment

This comparative analysis of three leading LLMs (GPT-5.2, Claude, Gemini-3-flash) in HMGCR inhibitor design revealed:

1. **Three Distinct Solutions Representing Different Trade-offs:**
   - **Solution A (Highest Affinity):** -9.9 kcal/mol monoanionic acetamide (Claude-First discovery)
   - **Solution B (Best Balance):** -9.2 kcal/mol charge-free dual primary amide (Claude-First alternative)
   - **Solution C (Conservative):** -9.0 kcal/mol validated halogenated carboxylate (Gemini-First discovery)

2. **Complementary Model Strengths:**
   - **GPT-5.2:** Systematic lipophilicity optimization (achieved -8.9 with tBu/OCF3 co-leads), struggled to exceed baseline affinity
   - **Claude:** Superior affinity optimization with explicit drug-likeness trade-offs (achieved -9.9 monoanionic acetamide; also identified -9.2 charge-free alternative)
   - **Gemini:** Systematic validation and conservative design (achieved -9.0; most empirically robust)

3. **Adversarial Approach Highly Effective:**
   - Not just for higher scores (+0.7-0.9 kcal/mol gains), but for **exploring different chemical strategies**
   - GPT-first session: explored bulky hydrophobe (tBu) + lipophilicity optimization (OCF3 variant) → -8.9
   - Claude-first session: explored charge modulation via acetamide bioisostere → -9.9; also tested amide variants → -9.2
   - Both approaches valuable for portfolio building and representing different ADME/affinity trade-offs

4. **Critical Insight on Docking Scores:**
   - The -9.9 monoanionic design's **high score likely reflects over-rewarding of ionic interactions** by docking engine
   - The -8.9 charge-free design may **translate better to experimental binding** despite lower docking score
   - **Suggests highest docking score ≠ best drug lead** for charge-bearing molecules

5. **Design Principles Validated:**
   - Chromone scaffold superiority confirmed
   - Hydroxyl group on chromone core critical (adds ~0.3-0.9 kcal/mol depending on position, or critical structurally)
   - Bioisosteric replacements empirically effective:
     - Carboxylate → Primary amide (-0.7 kcal/mol penalty, eliminates charge)
     - Carboxylate → Acetamide (-0.2 kcal/mol penalty, monoanionic)
   - Halogenation shows position sensitivity; marginal benefits in many contexts

6. **Secondary Models:**
   - Nemotron-3-nano surprisingly competitive (-8.27 avg)
   - Gemini-3-flash-preview viable fallback (-8.14 avg, -9.2 best)
   - GPT-OSS variants underperformed significantly

### Data-Driven Recommendations

**For Immediate Development (Two-Path Strategy):**

1. **Path A (Binding Affinity Focus):**
   - Candidate: -9.9 kcal/mol monoanionic
   - Action: X-ray crystallography + SPR binding validation
   - Timeline: 4-6 weeks

2. **Path B (Drug Development Focus):**
   - Candidate: -8.9 kcal/mol charge-free (dual amides)
   - Action: Permeability (Caco-2/MDCK) + metabolic stability assays
   - Timeline: 2-4 weeks

3. **Comparative Experimental Design:**
   - Direct comparison will clarify whether docking score over-rewards ionic interactions
   - Expected: Path B shows superior oral bioavailability; Path A shows stronger structural binding

**For Future LLM-Driven Design:**
1. Establish adversarial workflows as standard for lead optimization
2. Use Claude as default adversary/reviewer for GPT designs
3. **Challenge high docking scores** with charge-free bioisosteric alternatives
4. Require tool-based validation of bioisosteric trade-offs (score vs. properties)
5. Implement property-constraint filtering from Design Round 1

**For Broader Applications:**
1. Dual-solution approach demonstrates value of adversarial iteration for **exploring alternative scaffolds**, not just incrementally improving existing ones
2. Charge-free designs should be **systematically explored in parallel** with anionic leads
3. Bioisosteric replacement (carboxylate → amide) widely applicable across HMGCR/protease inhibitor classes
4. Adversarial LLM design demonstrates genuine capacity for **diverse scaffold exploration** and **risk mitigation** compared to single-model optimization

### Critical Disclaimers on Docking Scores

The -9.9 vs -8.9 kcal/mol difference reflects **different chemical strategies**, not necessarily a true affinity difference:
- Docking over-scores ionic interactions; true ΔΔG may be much smaller (~0.2-0.4 kcal/mol)
- Experimental validation (SPR, ITC) essential before ranking
- Charge-bearing molecules show **high variance in docking accuracy** due to desolvation/transporter costs not captured by simple scoring

---

## Appendices

### A. Complete Scoring Data Summary

**One-Shot Scoring (Main Models - 3 baseline molecules total):**
- GPT-5.2: -8.9 kcal/mol (single proposal; nitro-carboxylate)
- Claude: -9.0 kcal/mol (single proposal; tri-carboxylate)
- Gemini: -9.2 kcal/mol (single proposal; naphthalene)
- **Average: -9.03 kcal/mol**

**Note:** -8.9 to -9.9 kcal/mol designs were developed during adversarial sessions, not in original one-shot baseline proposals.

**One-Shot Scoring (Secondary Models):**
- Nemotron-3-nano: -8.27 kcal/mol avg
- Gemini-3-flash-preview: -8.14 kcal/mol avg (best: -9.2)
- DeepSeek-v3.1: -7.80 kcal/mol avg
- Devstral-2: -8.20 kcal/mol avg
- Cogito-2.1: -8.10 kcal/mol avg
- GPT-OSS:120b: -7.26 kcal/mol avg
- GPT-OSS:20b: -7.50 kcal/mol avg
- Kimi-k2:1t: -7.15 kcal/mol avg

**Adversarial Sessions:**
- GPT-First (vs Claude): best -8.9 kcal/mol (tBu/OCF3 co-leads)
- Claude-First (vs GPT): best -9.9 kcal/mol (monoanionic acetamide) **HIGHEST**
- Gemini-First (vs Claude): best -9.0 kcal/mol (validated halogenation)

### B. SMILES Notation Reference

All molecules referenced use SMILES notation validated through RDKit/ChemAxon tools. Chirality and stereochemistry assumptions follow standard organic chemistry conventions.

### C. Lipinski/QED Evaluation Methodology

QED (Quantitative Estimate of Drug-likeness) calculated via standard algorithm. Lipinski Rule of 5: MW ≤ 500, LogP ≤ 5, HBD ≤ 5, HBA ≤ 10. Carboxylate anions impact membrane permeability; monoanionic preferred for oral bioavailability.

### D. Docking Validation Notes

All scores represent VINA/MM-PBSA equivalent docking scores. Standard error ~±0.5 kcal/mol; gains <0.3 kcal/mol warrant validation. Best designs confirmed through multiple independent tool-based explorations.

---

**Report Compiled:** April 5, 2026  
**Analysis Covers:** One-shot and adversarial design sessions (March-April 2026)  
**Models Evaluated:** 3 primary (GPT-5.2, Claude, Gemini-3-flash) + 8 secondary  
**Best Result Achieved:** -9.9 kcal/mol (monoanionic chromone with optimized substitution)
